Glecirasib

Glecirasib (Compound 1-2; JAB-21822) is an orally active and potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer[1][2][3][4].

Product Specifications

CAS Number

[2657613-87-9]

Product Name Alternative

JAB-21822; KRAS G12C inhibitor 36

UNSPSC

12352005

Target

Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/glecirasib.html

Purity

99.20

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N#CC1=C(N2CCN(CC2)C(C=C)=O)C3=C(N=C(C4=C(N)C(F)=C(F)C(F)=C4F)C(Cl)=C3)N(C5=C(C)C=CN=C5C(C)C)C1=O

Molecular Formula

C31H26ClF4N7O2

Molecular Weight

640.03

References & Citations

[1]Amin LI, et al. Kras mutant protein inhibitors. Patent WO2021121367A1.|[2]Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors[J]. 2024.|[3]Ma C, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. J Med Chem. 2024 Aug 22;67 (16) :13534-13549. |[4]Fuerst M L. Glecirasib Induces Promising Efficacy in Patients With Advanced Lung Cancer[J]. 2024.